Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.

Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y, Miner JH, Leuschner I, Engers R, Everding AS, Bulla M, Royer-Pokora B.

J Am Soc Nephrol. 2007 Mar;18(3):719-29. Epub 2007 Jan 31.

2.

Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.

Patek CE, Fleming S, Miles CG, Bellamy CO, Ladomery M, Spraggon L, Mullins J, Hastie ND, Hooper ML.

Hum Mol Genet. 2003 Sep 15;12(18):2379-94. Epub 2003 Jul 22.

PMID:
12915483
3.

A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development.

Natoli TA, Liu J, Eremina V, Hodgens K, Li C, Hamano Y, Mundel P, Kalluri R, Miner JH, Quaggin SE, Kreidberg JA.

J Am Soc Nephrol. 2002 Aug;13(8):2058-67.

4.

VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells.

Cash J, Korchnak A, Gorman J, Tandon Y, Fraizer G.

Oncol Rep. 2007 Jun;17(6):1413-9.

PMID:
17487399
5.

A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.

Heathcott RW, Morison IM, Gubler MC, Corbett R, Reeve AE.

Hum Mutat. 2002 Apr;19(4):462. Review.

PMID:
11933209
6.

Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome.

Swiatecka-Urban A, Mokrzycki MH, Kaskel F, Da Silva F, Denamur E.

Pediatr Nephrol. 2001 Aug;16(8):627-30.

PMID:
11519891
7.

A proteomic investigation of glomerular podocytes from a Denys-Drash syndrome patient with a mutation in the Wilms tumour suppressor gene WT1.

Viney RL, Morrison AA, van den Heuvel LP, Ni L, Mathieson PW, Saleem MA, Ladomery MR.

Proteomics. 2007 Mar;7(5):804-15.

PMID:
17295355
8.

WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis.

Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, Hastie ND, Schedl A.

Hum Mol Genet. 2002 Mar 15;11(6):651-9.

PMID:
11912180
9.

Mother-to-child transmitted WT1 splice-site mutation is responsible for distinct glomerular diseases.

Denamur E, Bocquet N, Mougenot B, Da Silva F, Martinat L, Loirat C, Elion J, Bensman A, Ronco PM.

J Am Soc Nephrol. 1999 Oct;10(10):2219-23.

10.

Small glomeruli in WAGR (Wilms Tumor, Aniridia, Genitourinary Anomalies and Mental Retardation) syndrome.

Dahan K, Kamal M, Noël LH, Jeanpierre C, Gubler MC, Brousse N, Mariaud de Serre NP.

Am J Kidney Dis. 2007 Jun;49(6):793-800.

PMID:
17533022
11.

Clinical pictures and novel mutations of WT1-associated Denys-Drash syndrome in two Chinese children.

Yue Z, Pei Y, Sun L, Huang W, Huang H, Hu B, Yang J, Jiang X, Mo Y, Chen S, Lai KN, Wang Y.

Ren Fail. 2011;33(9):910-4. doi: 10.3109/0886022X.2011.605528. Epub 2011 Aug 18.

PMID:
21851196
12.

WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.

Yang Y, Jeanpierre C, Dressler GR, Lacoste M, Niaudet P, Gubler MC.

Am J Pathol. 1999 Jan;154(1):181-92.

13.

The dysregulated glomerular cell growth in Denys-Drash syndrome.

Yang AH, Chen JY, Chen BF.

Virchows Arch. 2004 Sep;445(3):305-14. Epub 2004 Jul 1.

PMID:
15232745
14.

WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.

Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DA.

Curr Biol. 2001 Nov 13;11(22):1805-9.

15.

New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes.

Morrison AA, Viney RL, Saleem MA, Ladomery MR.

Am J Physiol Renal Physiol. 2008 Jul;295(1):F12-7. doi: 10.1152/ajprenal.00597.2007. Epub 2008 Apr 2. Review.

16.

Donor splice-site mutations in WT1 are responsible for Frasier syndrome.

Barbaux S, Niaudet P, Gubler MC, Grünfeld JP, Jaubert F, Kuttenn F, Fékété CN, Souleyreau-Therville N, Thibaud E, Fellous M, McElreavey K.

Nat Genet. 1997 Dec;17(4):467-70.

PMID:
9398852
17.

Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein.

Cui TG, Foster RR, Saleem M, Mathieson PW, Gillatt DA, Bates DO, Harper SJ.

Am J Physiol Renal Physiol. 2004 Apr;286(4):F767-73. Epub 2003 Nov 25.

18.

A murine model of Denys-Drash syndrome reveals novel transcriptional targets of WT1 in podocytes.

Ratelade J, Arrondel C, Hamard G, Garbay S, Harvey S, Biebuyck N, Schulz H, Hastie N, Pontoglio M, Gubler MC, Antignac C, Heidet L.

Hum Mol Genet. 2010 Jan 1;19(1):1-15. doi: 10.1093/hmg/ddp462.

PMID:
19797313
19.

Transcriptional regulation of PDGF-A and TGF-beta by +KTS WT1 deletion mutants and a mutant mimicking Denys-Drash syndrome.

Jin DK, Kang SJ, Kim SJ, Bang EH, Hwang HZ, Tadokoro K, Yamada M, Kohsaka T.

Ren Fail. 1999 Nov;21(6):685-94.

PMID:
10586431
20.

Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms.

Klamt B, Koziell A, Poulat F, Wieacker P, Scambler P, Berta P, Gessler M.

Hum Mol Genet. 1998 Apr;7(4):709-14.

PMID:
9499425

Supplemental Content

Support Center